Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
https://orcid.org/0000-0002-0916-893X
AbstractThe development of a globally effective COVID‐19 vaccine faces significant challenges, particularly in redirecting the B‐cell response from immunodominant yet variable regions of viral proteins toward their conserved domains. To address this, an integrated strategy is implemented that combines classical B‐cell epitope prediction with protein‐antibody cluster docking and antibody titer analysis from 30 vaccinated and convalescent individuals. This approach yields stable immunodominant and immunoprevalent B‐cell epitopes capable of eliciting robust antibody responses in BALB/c mice and effectively neutralizing pseudoviruses expressing the Spike protein of SARS‐CoV‐2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron. To achieve a broader T‐cell‐based immune response, promiscuous T‐cell epitopes are identified by integrating classical T‐cell epitope predictions, differential scanning fluorimetry, and peptide‐MHC structural analysis. Unique peptides with conserved MHC‐anchoring residues are identified, enabling binding to a spectrum of MHC‐I and MHC‐II haplotypes. These peptides elicit strong interferon gamma responses in human peripheral blood mononuclear cells and demonstrate cross‐species efficacy by activating both CD4+ and CD8+ T‐cells in BALB/c mice. Collectively, these findings highlight the significance of innovative vaccine strategies targeting immunodominant/immunoprevalent B‐cell and promiscuous T‐cell epitopes to drive broad and robust humoral and cellular immune responses against a wide range of SARS‐CoV‐2 variants.
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
https://orcid.org/0000-0002-0916-893X
AbstractThe development of a globally effective COVID‐19 vaccine faces significant challenges, particularly in redirecting the B‐cell response from immunodominant yet variable regions of viral proteins toward their conserved domains. To address this, an integrated strategy is implemented that combines classical B‐cell epitope prediction with protein‐antibody cluster docking and antibody titer analysis from 30 vaccinated and convalescent individuals. This approach yields stable immunodominant and immunoprevalent B‐cell epitopes capable of eliciting robust antibody responses in BALB/c mice and effectively neutralizing pseudoviruses expressing the Spike protein of SARS‐CoV‐2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron. To achieve a broader T‐cell‐based immune response, promiscuous T‐cell epitopes are identified by integrating classical T‐cell epitope predictions, differential scanning fluorimetry, and peptide‐MHC structural analysis. Unique peptides with conserved MHC‐anchoring residues are identified, enabling binding to a spectrum of MHC‐I and MHC‐II haplotypes. These peptides elicit strong interferon gamma responses in human peripheral blood mononuclear cells and demonstrate cross‐species efficacy by activating both CD4+ and CD8+ T‐cells in BALB/c mice. Collectively, these findings highlight the significance of innovative vaccine strategies targeting immunodominant/immunoprevalent B‐cell and promiscuous T‐cell epitopes to drive broad and robust humoral and cellular immune responses against a wide range of SARS‐CoV‐2 variants.
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
https://orcid.org/0000-0002-0916-893X
AbstractThe development of a globally effective COVID‐19 vaccine faces significant challenges, particularly in redirecting the B‐cell response from immunodominant yet variable regions of viral proteins toward their conserved domains. To address this, an integrated strategy is implemented that combines classical B‐cell epitope prediction with protein‐antibody cluster docking and antibody titer analysis from 30 vaccinated and convalescent individuals. This approach yields stable immunodominant and immunoprevalent B‐cell epitopes capable of eliciting robust antibody responses in BALB/c mice and effectively neutralizing pseudoviruses expressing the Spike protein of SARS‐CoV‐2 variants of concern, including Alpha, Beta, Gamma, Delta, and Omicron. To achieve a broader T‐cell‐based immune response, promiscuous T‐cell epitopes are identified by integrating classical T‐cell epitope predictions, differential scanning fluorimetry, and peptide‐MHC structural analysis. Unique peptides with conserved MHC‐anchoring residues are identified, enabling binding to a spectrum of MHC‐I and MHC‐II haplotypes. These peptides elicit strong interferon gamma responses in human peripheral blood mononuclear cells and demonstrate cross‐species efficacy by activating both CD4+ and CD8+ T‐cells in BALB/c mice. Collectively, these findings highlight the significance of innovative vaccine strategies targeting immunodominant/immunoprevalent B‐cell and promiscuous T‐cell epitopes to drive broad and robust humoral and cellular immune responses against a wide range of SARS‐CoV‐2 variants.
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
Advanced Science
Shah, Masaud (Autor:in) / Moon, Sung Ung (Autor:in) / Shin, Ji‐Yon (Autor:in) / Choi, Ji‐Hye (Autor:in) / Kim, Doyoon (Autor:in) / Woo, Hyun Goo (Autor:in)
27.02.2025
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
DNA vaccines for targeting bacterial infections
| British Library Conference Proceedings | 2010